Author

Ziqun Liu

Chinese Academy of Sciences

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:metabolomics· 1

Frequent Co-Authors

Denglong WuiD· 2 shared Hanchu YeiD· 2 shared Xinan WangiD· 2 shared zhenfei liiD· 2 shared Chen Wang· 1 shared Chengchao Ruan· 1 shared Chunqiao SuniD· 1 shared Feifei LiniD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Denglong WuORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

scPRIME-seq uncovers synchronized multimodal molecular collapse facilitated by pre-neoplastic epigenetic burden in prostate cancer

Shengdi Li, Ziqun Liu, Yingying Xie, Xinan Wang, Hanchu Ye, Xingyong Ma, Ming Tan, Denglong Wu, 黄盛松, zhenfei li

The paper introduces scPRIME-seq, a multimodal single-cell platform, and finds pre-neoplastic epigenetic changes drive tumor progression in prostate cancer.

bioRxiv · Oct 9, 2026 · PreprintCancer Biology

A patient-centric therapeutic paradigm uncouples prostate cancer suppression from systemic metabolic collapse

Ziqun Liu, Hanchu Ye, Haoran Hu, Wuhong Chen, Chen Wang, Yongfeng Yang, Xinran Yan, Longlong Chen, Yang Wang, Yumeng Yang, Chunqiao Sun, Yaqing Bai, Haiyang Hou, Xinan Wang, Jun Cao, , Zhenfei Li

This paper identifies metabolic dysregulation caused by abiraterone in prostate cancer patients and develops Lifehug-9892 to suppress tumors while preserving systemic metabolic health.

bioRxiv · Sep 2, 2026 · PreprintCancer Biology